乳酸依沙吖啶 | 1837-57-6

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 消毒防腐药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 乳酸依沙吖啶
• 中文别名: 雷佛奴尔；雷凡醇；6,9-二胺-2-乙氧吖啶；乳酸依沙吖啶(一水物)；2-乙氧基-6,9-二氨基吖啶乳酸盐
• 英文名称: ethacridine lactate
• 英文别名: rivanol；acrinol；6,9-diamino-2-ethoxyacridine-DL-lactate；2-ethoxy-6,9-diamino-acridine lactate；2-Ethoxy-6,9-diamino-acridinium-lactat；7-ethoxyacridin-10-ium-3,9-diamine;2-hydroxypropanoate
• CAS: 1837-57-6
• 化学式: C₃H₆O₃*C₁₅H₁₅N₃O
• 分子量: 343.382
• InChiKey: IYLLULUTZPKQBW-UHFFFAOYSA-N

物化性质

• 熔点：
  235°C
• 沸点：
  478.66°C (rough estimate)
• 密度：
  1.2764 (rough estimate)
• 溶解度：
  DMSO:84.5(最大浓度 mg/mL);246.08(最大浓度 mM)水:69.0(最大浓度 mg/mL);104.84(最大浓度 mM)
• 碰撞截面：
  156.3 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，没有已知危险反应，避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xn,Xi
• WGK Germany：
  3
• RTECS号：
  UT6410000
• 海关编码：
  2933990090
• 安全说明：
  S24/25,S26,S36/37/39,S37/39
• 危险类别码：
  R22,R20/21/22,R40,R36/37/38
• 储存条件：
  请将贮藏器密封，并存放在阴凉、干燥处。确保工作环境有良好的通风或排气设施。

SDS

Name:	6 9-Diamino-2-Ethoxyacridine Lactate 95% (Titr.) Material Safety Data Sheet
Synonym:	6,9-Acridinediamine, 2-Ethoxy-, 2-Hydroxypropanote; Acrinol; Ethodin
CAS:	1837-57-6

Section 1 - Chemical Product MSDS Name:6 9-Diamino-2-Ethoxyacridine Lactate 95% (Titr.) Material Safety Data Sheet
Synonym:6,9-Acridinediamine, 2-Ethoxy-, 2-Hydroxypropanote; Acrinol; Ethodin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1837-57-6	Propanoic acid, 2-hydroxy-, compd. wit	95	217-408-1

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1837-57-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C18H21N3O4.H2O
Molecular Weight: 361.39

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1837-57-6: OD4725000 LD50/LC50:
Not available.
Carcinogenicity:
Propanoic acid, 2-hydroxy-, compd. with7-ethoxy-3,9-acridine - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 1837-57-6: No information available.
Canada
CAS# 1837-57-6 is listed on Canada's NDSL List.
CAS# 1837-57-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1837-57-6 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

乳酸依沙吖啶概述

乳酸依沙吖啶（Ethacridine lactate），又称利凡诺，是一种吖啶类碱性染料，被认为是染料类中最为有效的防腐剂。未解离成阳离子时，该物质不具备抗菌活性；当其在碱性氮基上带正电荷时，则对革兰阳性菌表现出最强的抑菌作用，并能有效对抗多种化脓菌。乳酸依沙吖啶的抗菌活性与溶液pH值及药物的解离常数相关。通常以0.1%～0.3%水溶液冲洗或使用浸药纱布湿敷来治疗皮肤和黏膜创面感染，在治疗浓度下对组织无损害，但抗菌作用产生较慢，可牢固吸附在黏膜和创面上，作用可持续约一天。此外，其活性会在有机物存在时增强。

理化性质

乳酸依沙吖啶是一种黄色结晶性粉末，几乎无臭且味道苦涩。该物质在水中溶解，在热水中易溶，在乙醇中微溶，在乙醚中不溶。其结构式如下图所示：

临床应用

乳酸依沙吖啶主要用于创面和黏膜的消毒。相关内容由Chemicalbook的侍艳编辑整理（2015-11-17）。

用法用量

将乳酸依沙吖啶配制成0.1%水溶液后，适量涂抹于患处即可。

注意事项

1. 溶液在光照下可分解生成剧毒物质。若肉眼观察到本品变为褐绿色，则表明已分解。
2. 当溶液中氯化钠浓度高于0.5%时，乳酸依沙吖啶可能从溶液中析出。
3. 该溶液遇碱和碘液易产生沉淀。
4. 长期使用可能会延缓伤口愈合。

用途：

消毒防腐药。

反应信息

• 作为反应物：
  描述：

  乳酸依沙吖啶 在 N-溴代丁二酰亚胺(NBS) 、 溶剂黄146 作用下， 以85%的产率得到6,9-Diamino-5-brom-2-ethoxy-acridin
  参考文献：
  名称：

  Moehrle; Von Der Lieck-Waldheim, Scientia Pharmaceutica, 1997, vol. 65, # 1-2, p. 11 - 20

  摘要：

  DOI：
• 作为产物：
  描述：

  乳酸 、 依沙吖啶 以 水 、 异丙醇 为溶剂， 以12.58 g的产率得到乳酸依沙吖啶
  参考文献：
  名称：

  CN115850171

  摘要：

  公开号：

文献信息

• Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2601941A1

  公开（公告）日：2013-06-12

  The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

  本发明涉及beta-O/S/N脂肪酸及其衍生物，特别是如本文所述和定义的公式(I)化合物，及其医药用途，包括用于治疗或预防细菌以及原生动物感染，特别是治疗或预防革兰氏阳性细菌和/或革兰氏阴性细菌引起的感染和传染病以及与之相关的感染和传染病。该发明还涉及这些化合物用于预防或消除生物膜。
• [EN] BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS<br/>[FR] COMPOSÉS À BASE DE BÊTA-O/S/N ACIDES GRAS EN TANT QU'AGENTS ANTIBACTÉRIENS ET ANTI-PROTOZOAIRES
  申请人：UNIV MUENCHEN L MAXIMILIANS

  公开号：WO2013083724A1

  公开（公告）日：2013-06-13

  The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

  本发明涉及β-O/S/N脂肪酸及其衍生物，特别是如本文所述和定义的公式(I)化合物，以及它们的医药用途，包括用于治疗或预防细菌以及原生动物感染，尤其是治疗或预防革兰氏阳性菌和/或革兰氏阴性菌感染以及由革兰氏阳性菌和/或革兰氏阴性菌引起的传染病。本发明进一步涉及使用这些化合物来预防或消除生物膜。
• Thiirane and michael acceptor compounds and their medical use
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2607361A1

  公开（公告）日：2013-06-26

  The present invention relates to thiirane or Michael acceptor compounds, including the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising these compounds, as well as their medical use, particularly their use in the treatment or prevention of a bacterial infection, including, e.g., an infection with multidrug-resistant Staphylococcus aureus.

  本发明涉及噻环丙烯或迈克尔受体化合物，包括本文描述和定义的式(I)化合物，以及包含这些化合物的药物组合物，以及它们的医药用途，特别是它们在治疗或预防细菌感染中的用途，例如对多重耐药金黄色葡萄球菌感染的用途。
• GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY
  申请人：Cai Jianfeng

  公开号：US20150274782A1

  公开（公告）日：2015-10-01

  The present invention is directed to a novel class of antimicrobial agents called γ-AApeptides. The current invention provides various categories of γ-AApeptides, for example, linear γ-AApeptides, cyclic γ-AApeptides, and lipidated γ-AApeptides. γ-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. γ-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed γ-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.

  本发明涉及一种新型类别的抗微生物药物，称为γ-AA肽。当前发明提供了各种类别的γ-AA肽，例如线性γ-AA肽、环状γ-AA肽和脂质化γ-AA肽。本发明的γ-AA肽被设计为具有抗微生物活性，同时稳定且无毒。γ-AA肽似乎也不会导致被治疗微生物体内微生物产生抗药性。因此，所披露的γ-AA肽可用于治疗与病原微生物相关的各种医疗状况。
• METHOD FOR PREPARING HIGH ABSORBENT HYDROCOLLOID
  申请人：LEE Soo-Chang

  公开号：US20070281029A1

  公开（公告）日：2007-12-06

  The present invention relates to a method for preparing a hydrocolloid which may be applied to skin, particularly, wounds. The present invention comprises a first step of preparing a pre-polymer having a viscosity of 200 cps˜10,000 cps by mixing an acryl monomer and an ultraviolet initiator and irradiating on the mixture with ultraviolet rays; a second step of preparing a complex by mixing at least an ultraviolet initiator and a high water absorbing substance with the resulting pre-polymer; and a third step of polymerizing the complex with irradiating ultraviolet rays. The thus prepared hydrocolloid of the present invention has an excellent absorbency as well as self-adhesiveness, is not remained as any residue upon removing it from the skin (wound) and has less skin irritation, without employing any tackifier.

  本发明涉及一种制备适用于皮肤，特别是伤口的羟基胶的方法。本发明包括以下步骤：第一步，通过混合丙烯酸酯单体和紫外线引发剂，并用紫外线照射混合物，制备粘度为200 cps˜10,000 cps的预聚合物；第二步，通过将至少一个紫外线引发剂和高吸水性物质与所得的预聚合物混合，制备复合物；第三步，通过紫外线照射聚合复合物。本发明制备的羟基胶具有优异的吸收性和自粘性，从皮肤（伤口）上取下时不会留下任何残留物，并且几乎不会引起皮肤刺激，而不需要使用任何粘合剂。

表征谱图